CNBC
06 Nov 2026, 11:47 UTC · 59m ago
Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
Impact · against what's priced in
Moderna's outlook raise and return to profitability provide a fundamental lift to its respiratory vaccine franchise, which the market previously viewed as declining. Merck remains largely unaffected as the news focuses on Moderna's operational beats rather than new clinical breakthroughs for their shared cancer vaccine.
- MRNA+0.40
Challenges what's priced in
- The price assumes
The current respiratory vaccine franchise, which generated $1.94 billion in FY2025 revenue despite a 39.2% year-over-year decline.
The market has been pricing the respiratory franchise as a declining business; however, the 29% Q3 revenue jump to $1.31 billion and the guidance raise to 15%-25% growth for 2026 suggest the franchise has stabilized and is regaining momentum.
What MRNA's price assumes · Sep 11
